While several studies have assessed the efficacy of targeting Ang2 in combination with anti-VEGF therapy [42], we tested the use of soluble Tie2 based on the rational that soluble Tie2 might also block the association between angiopoieitins and integrins previously associated with invasiveness in gliomas [39], and that other angiopoietins have been reported to have a role in glioma resistance to therapies [43]. The gene discussed is ANGPT2; the disease is central nervous system cancer.